Spots Global Cancer Trial Database for A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms
Official Title: A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms
Study ID: NCT04755543
Conditions
Study Description
Brief Summary: LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety, pharmacokinetics and preliminary efficacy of LP002 for the treatment of malignant digestive system neoplasms will be evaluated.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Henan Cancer Hospital & Insititute, Zhengzhou, Henan, China
Hubei Cancer Hospital & Insititute, Wuhan, Hubei, China
Liaoning Cancer Hospital & Insititute, Shenyang, Liaoning, China
The First Affiliated Hospital. Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
The First Affiliated Hospital. Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
